[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351813-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351813-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","improved-stage-specific-survival-in-screen-detected-breast-cancer-in-denmark-a-cohort-study","Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study","","Background: This cohort study examined whether survival improvements after breast cancer screening are driven solely by earlier stage detection and whether mortality can be predicted using stage and diagnosis date alone. Methods: Stage-specific net survival was compared among never-screened, symptomatic ever-screened, and screen-detected cases in Denmark using electronic health records from 2010–2022, converting excess mortality into net survival. Results: Survival differences were minimal for stages I–III, but reached about 40% at stage IV; treatment strongly correlated with outcomes. Conclusions: Higher stage IV survival in screen-detected cases suggests screening may not be too late.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/improved-stage-specific-survival-in-screen-detected-breast-cancer-in-denmark-a-cohort-study/351813/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/improved-stage-specific-survival-in-screen-detected-breast-cancer-in-denmark-a-cohort-study/351813.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study aim to answer about screening and survival?","Question",{"text":63,"@type":64},"The study tests whether improvements in survival from breast cancer screening are explained only by detecting cancers at earlier stages, and whether breast cancer mortality can be predicted using stage and diagnosis date alone.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were survival outcomes estimated in this Danish cohort?",{"text":68,"@type":64},"Researchers compared stage-specific net survival across never-screened, symptomatic ever-screened, and screen-detected groups using individual-level electronic health records from 2010 to 2022, then transformed excess mortality into net survival.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings for survival by stage, especially stage IV?",{"text":72,"@type":64},"Differences between symptomatic and screen-detected cases were minimal for stages I–III, but stage IV showed a large difference (around 40%). Five-year net survival for stage IV screen-detected women was 74.7%, resembling stage IIIc survival among never-screened symptomatic women.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351813,1790147736,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","JNCI: Journal of the National Cancer Institute, 2026, 118(6), 1073–1080  \n[https://doi.org/10.1093/jnci/djaf377](https://doi.org/10.1093/jnci/djaf377)  \nAdvance Access Publication Date: February 19, 2026  \nArticle  \nImproved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study  \nAmy Tickle , PhD􀀃 ,1, Judith Offman , PhD2, Bernard North , PhD2, Susanne FoghJørgensen , PhD3,4, Sisse Njor , PhD3,4, 5, Peter Sasieni , PhD2  \n1Comprehensive Cancer Centre, King’s College London, Guy’s Campus, London, United Kingdom 2Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom 3Department of Regional Health Research, University of Southern Denmark, Odense, Denmark  \n4Research Unit for Screening and Epidemiology, Department for Biochemistry and Immunology, University Hospital of Southern Denmark, Vejle, Denmark 5Department of Clinical Medicine, Aarhus University, Aarhus, Denmark  \n􀀃 Corresponding author: Amy Tickle, PhD, Amsterdam UMC, Vrije Universiteit, Van der Boechorststraat 7, 1081 BT, Amsterdam ([a.r.tickle@amsterdamumc.nl](a.r.tickle@amsterdamumc.nl))  \nAbstract  \nBackground: This study examined whether breast cancer survival improvements with screening are explained solely by detection at early stages and whether mortality can be predicted using stage and diagnosis date alone.  \nMethods: We compared stage-specific net survival between never-screened, symptomatic ever-screened (past attenders and interval cancers), and screen-detected breast cancer cases in Denmark using individual-level electronic health records from January 1, 2010 to December 31, 2022. Lifetables were generated from women without breast cancer, separately for never-screened and everscreened women. Age-specific all-cause mortality rates were used to calculate excess mortality in women with breast cancer, which was then transformed into net survival.  \nResults: Of 817 128 women, 32 827 had breast cancer, with 8% presenting as stage III or IV. Survival differences between symptomatic and screen-detected cases were minimal for stages I–III but reached 40% at stage IV, with 5-year net survival for stage IV screendetected women (74.7%) resembling stage IIIc symptomatic survival in never-screened women (72.6%) . Survival from stage IV breast cancer was strongly associated with treatment, with median survival (years) of 4.4-6.0 with surgery, 1.6-2.2 with nonsurgical treatment, and 0.03-0.13 with no treatment; 67% of screen-detected patients received surgery (compared with 23% of never-screened and 27% of symptomatic ever-screened) .  \nConclusions: Greater survival in screen-detected stage IV cases suggests that breast cancer screening may not have come too late and deserves to be investigated further. Predicting breast cancer mortality using stage at diagnosis and stage-specific survival (without differentiating by route to diagnosis) will underestimate the impact of breast screening on mortality.  \nKeywords: breast screening, mammography, organised breast screening programs, stage at diagnosis, stage-specific survival, net survival, stage 4, breast cancer, metastatic, metastatisis, late-stage, screen-detected, route to diagnosis, oligometastatic, excess mortality  \nIntroduction  \nOrganized breast cancer screening programs provide women with national access to 2-view, digital mammography, followed by diagnostic assessment for abnormal screens. The ages at which screening is offered varies between countries,1-3 while screening intervals range from 1-3 years (annually in the United States, biennially in Denmark, and triennially in the United Kingdom) .  \nIn Denmark, breast screening implementation became mandatory at county level from 2007, with national rollout being required by the end of 2009. Since then, biennial breast cancer screening has been offered to female residents aged 50-69 years. This service is administered separately by 5 administrative regions, with women with detected abnormalities be","cbCaifcfZRVAk2o2","https://ap.wps.com/l/cbCaifcfZRVAk2o2","pdf",933873,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Breast screening programs in Denmark\n## Rationale and study aim\n# Methods\n## Study design","[{\"question\":\"What question does the study aim to answer about screening and survival?\",\"answer\":\"The study tests whether improvements in survival from breast cancer screening are explained only by detecting cancers at earlier stages, and whether breast cancer mortality can be predicted using stage and diagnosis date alone.\"},{\"question\":\"How were survival outcomes estimated in this Danish cohort?\",\"answer\":\"Researchers compared stage-specific net survival across never-screened, symptomatic ever-screened, and screen-detected groups using individual-level electronic health records from 2010 to 2022, then transformed excess mortality into net survival.\"},{\"question\":\"What were the key findings for survival by stage, especially stage IV?\",\"answer\":\"Differences between symptomatic and screen-detected cases were minimal for stages I–III, but stage IV showed a large difference (around 40%). Five-year net survival for stage IV screen-detected women was 74.7%, resembling stage IIIc survival among never-screened symptomatic women.\"}]","Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study | PDF",1790096042,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a592c7ac56b90c8aa877c744af27073d.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a64ab1b76f021129f7fb04f36f25a3a8.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e442e0a834d9b9f880adbcf66245f6df.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73bf4fbecf073c75c6b9fd7b0ae6f2db.webp",980,1287]